MUK four

• Research type

  Research Study

• Full title

  A Phase II Trial of combination treatment with Vorinostat, Bortezomib and Dexamethasone in participants with Relapsed Multiple Myeloma

• IRAS ID

  91788

• Contact name

  Faith Davies

• Sponsor organisation

  Leeds Teaching Hospitals NHS Trust

• Eudract number

  2011-005361-20

• ISRCTN Number

  ISRCTN08577602

• Clinicaltrials.gov Identifier

  NCT01720875

• Research summary

  Bortezomib is an established treatment in multiple myeloma; it is common practice in the UK to administer dexamethasone with bortezomib. This practice is based on data that supports improved response rates with this combination. Recent trial data indicates that the addition of vorinostat to bortezomib treatment overcomes treatment resistance to bortezomib. Furthermore, it seems likely that when vorinostat is introduced into UK practice in combination with bortezomib, there will be a desire to use it in combination with dexamethasone. As such this current trial is designed to investigate the efficacy, safety and tolerability of combination treatment with vorinostat, bortezomib and dexamethasone in patients with relapsed and relapsed refractory myeloma.

• REC name

  London - Fulham Research Ethics Committee

• REC reference

  12/LO/1901

• Date of REC Opinion

  31 Jan 2013

• REC opinion

  Further Information Favourable Opinion